PMC:7696151 / 69019-69327 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1973","span":{"begin":293,"end":301},"obj":"Species"},{"id":"1988","span":{"begin":34,"end":41},"obj":"Chemical"},{"id":"1989","span":{"begin":123,"end":137},"obj":"Chemical"},{"id":"1990","span":{"begin":154,"end":157},"obj":"Chemical"},{"id":"1991","span":{"begin":244,"end":251},"obj":"Chemical"}],"attributes":[{"id":"A1973","pred":"tao:has_database_id","subj":"1973","obj":"Tax:9606"},{"id":"A1988","pred":"tao:has_database_id","subj":"1988","obj":"MESH:D019788"},{"id":"A1989","pred":"tao:has_database_id","subj":"1989","obj":"MESH:D012460"},{"id":"A1990","pred":"tao:has_database_id","subj":"1990","obj":"MESH:D006886"},{"id":"A1991","pred":"tao:has_database_id","subj":"1991","obj":"MESH:D019788"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" joints was evaluated through the 18F-FDG PET method. It was found that cotreatment with 7.5–15 mg/week of MXT, 2 g/day of sulphasalazine, 5 mg/kg/day of HCQ and a low dose of oral PRD (under 10 mg/day) is associated with a reduction of 30% in 18F-FDG uptake measures on PET imaging in 81% of patients after "}